Authorized purpose: Ethos Treatment Management is indicated for managing and monitoring radiation-therapy treatment plans and sessions. Ethos Treatment Planning is indicated for generating and modifying radiation-therapy treatment plans. The Halcyon and Ethos Radiotherapy System are indicated for delivery of stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation is indicated for adults and pediatric patients.
Clinical role
Radiotherapy contouring, treatment planning, treatment management, image processing, or session support under qualified review and approval.
Images and patients
Radiotherapy Planning Imaging · Lesions, tumors, and conditions anywhere in the body; radiation-treatment plans and sessions
Key limitation
Keep in mind: The exact submission covers distinct treatment-management, treatment-planning, and radiotherapy-system functions; planning and delivery require qualified review, approval, and treatment controls.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Ethos Treatment Management is indicated for managing and monitoring radiation-therapy treatment plans and sessions. Ethos Treatment Planning is indicated for generating and modifying radiation-therapy treatment plans. The Halcyon and Ethos Radiotherapy System are indicated for delivery of stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation is indicated for adults and pediatric patients.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Lesions, tumors, and conditions anywhere in the body; radiation-treatment plans and sessions Input: Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.
Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals.
What does the software produce?Output: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
What is its most important limitation?Key limitation: The exact submission covers distinct treatment-management, treatment-planning, and radiotherapy-system functions; planning and delivery require qualified review, approval, and treatment controls.
Clinical takeaway. Clinical role: Ethos Treatment Management is indicated for managing and monitoring radiation-therapy treatment plans and sessions. Ethos Treatment Planning is indicated for generating and modifying radiation-therapy treatment plans. The Halcyon and Ethos Radiotherapy System are indicated for delivery of stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation is indicated for adults and pediatric patients.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing: hardware and software verification and validation per the FDA Quality System Regulation, ISO 13485, ISO 14971 and other recognized standards, with results showing conformance to applicable requirements specifications and properly functioning hazard safeguards, and electrical safety and EMC testing of the linear accelerators (IEC 60601-1 and IEC 60601-1-2). No discrepancy reports of Safety Intolerable or Customer Intolerable priority remained. It states no animal studies or clinical tests were included. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Ethos Treatment Management is indicated for managing and monitoring radiation-therapy treatment plans and sessions. Ethos Treatment Planning is indicated for generating and modifying radiation-therapy treatment plans. The Halcyon and Ethos Radiotherapy System are indicated for delivery of stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation is indicated for adults and pediatric patients.
The exact submission covers distinct treatment-management, treatment-planning, and radiotherapy-system functions; planning and delivery require qualified review, approval, and treatment controls.
The exact FDA document reports non-clinical testing: hardware and software verification and validation per the FDA Quality System Regulation, ISO 13485, ISO 14971 and other recognized standards, with results showing conformance to applicable requirements specifications and properly functioning hazard safeguards, and electrical safety and EMC testing of the linear accelerators (IEC 60601-1 and IEC 60601-1-2). No discrepancy reports of Safety Intolerable or Customer Intolerable priority remained. It states no animal studies or clinical tests were included. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance Data (Non-Clinical Testing): Hardware and software verification and validation testing was conducted according to the FDA Quality System Regulation (21 CFR §820), ISO 13485 quality Management System standard, ISO 14971 Risk Management Standard and the other FDA recognized consensus standards listed below." … "Test results showed conformance to applicable requirements specifications and assured hazard safeguards functioned properly.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical testing: hardware and software verification and validation per the FDA Quality System Regulation, ISO 13485, ISO 14971 and other recognized standards, with results showing conformance to applicable requirements specifications and properly functioning hazard safeguards, and electrical safety and EMC testing of the linear accelerators (IEC 60601-1 and IEC 60601-1-2). No discrepancy reports of Safety Intolerable or Customer Intolerable priority remained. It states no animal studies or clinical tests were included. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance Data (Non-Clinical Testing): Hardware and software verification and validation testing was conducted according to the FDA Quality System Regulation (21 CFR §820), ISO 13485 quality Management System standard, ISO 14971 Risk Management Standard and the other FDA recognized consensus standards listed below." … "Test results showed conformance to applicable requirements specifications and assured hazard safeguards functioned properly.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K192377 FDA decision evidence package for Ethos Treatment Management, Ethos Treatment Planning, Ethos Radiotherapy System, Halcyon
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationLesions, tumors, and conditions anywhere in the body; radiation-treatment plans and sessions
Scopeexact submission
Tested versionEthos Treatment Management, Ethos Treatment Planning, Ethos Radiotherapy System, Halcyon configuration described in K192377
IndependenceSponsor or vendor study
K192377
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K192377 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own press release (/press/releases/varian-closing) states it completed the acquisition of Varian Medical Systems, Inc. Corporate program statement; exact-release scope is not established.
Only radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K192377 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact submission covers distinct treatment-management, treatment-planning, and radiotherapy-system functions; planning and delivery require qualified review, approval, and treatment controls.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact submission covers distinct treatment-management, treatment-planning, and radiotherapy-system functions; planning and delivery require qualified review, approval, and treatment controls.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.
Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Modality
Radiotherapy Planning Imaging
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.
Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.
Authorized purpose: TAIMedImg DeepMets assists trained professionals by providing initial gross-tumor-volume contours on axial contrast-enhanced T1 brain MR images for radiation-treatment planning in adults with known brain metastases; the contours require thorough review and are not a replacement for manual contouring.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.